A Busy Week for Multiple Sclerosis News
It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
medicinova
MediciNova to Buy Avigen for $37 Million
Pharmaceutical company MediciNova announced that it will buy Avigen (AVGN) for $1.24 per share, approximately $37 million.